Evaluation of the Efficacy and Safety of Switching to Pasireotide in Patients With Acromegaly Inadequately Controlled With First-Generation Somatostatin Analogs.

Creative Commons License

Gadelha M., Bex M., Colao A., Garcia E. M. P., Poiana C., Jimenez-Sanchez M., ...More

Frontiers in endocrinology, vol.10, pp.931, 2020 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 10
  • Publication Date: 2020
  • Doi Number: 10.3389/fendo.2019.00931
  • Journal Name: Frontiers in endocrinology
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, BIOSIS, EMBASE, Directory of Open Access Journals
  • Page Numbers: pp.931
  • Keywords: somatostatin, pasireotide, acromegaly, growth hormone, insulin-like growth factor I, OCTREOTIDE-LAR, CLINICAL-PRACTICE, LANREOTIDE, DIAGNOSIS, THERAPY, HYPERGLYCEMIA, PATHOGENESIS, MULTICENTER
  • Dokuz Eylül University Affiliated: Yes


Introduction: Acromegaly is a rare, serious endocrine disorder characterized by excess growth hormone (GH) secretion by a pituitary adenoma and overproduction of insulin-like growth factor I (IGF-I). Transsphenoidal surgery is the treatment of choice, although many patients require additional interventions. First-generation somatostatin analogs (SSAs) are the current standard of medical therapy; however, not all patients achieve control of GH and IGF-I. Outcomes from a Phase IIIb open-label study of patients with uncontrolled acromegaly on first-generation SSAs switching to pasireotide are reported.